Skip to content

Study · Randomized controlled trial · n = 40 · 2017

7 results

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.

Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A

Diabetes care14 Sept 2017Cited by 89 (Europe PMC)

PMID28912305 (opens in a new tab)DOI10.2337/dc17-0589 (opens in a new tab)PepBankPUB-28912305
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, after comparable weight loss, liraglutide reduced visceral adipose tissue more than lifestyle counselling.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, liraglutide cut belly (visceral) fat more than lifestyle counselling at the same weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral adipose tissue reduction
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    reduction in VAT was significantly higher in the liraglutide arm than in the lifestyle arm (P = 0.028)
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, after comparable weight loss, liraglutide improved the beta-index more than lifestyle counselling.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, liraglutide improved insulin-producing cell function more than lifestyle counselling at the same weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell function (beta-index)
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    in parallel with a greater improvement in β-index (P = 0.021).
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, glycemic control as reflected by HbA1c was superimposable between liraglutide and lifestyle counselling.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, HbA1c control was about the same with liraglutide and with lifestyle counselling.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c after comparable weight loss
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    superimposable glycemic control, as reflected by HbA1c level (P = 0.60)
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, subcutaneous adipose tissue reduction did not differ between liraglutide and lifestyle counselling.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, loss of fat under the skin was similar with liraglutide and with lifestyle counselling.

    Peptide
    Liraglutide
    Outcome
    No significant changeSubcutaneous adipose tissue reduction
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    No differences were observed in SAT reduction (P = 0.64).
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, serum IGF-II rose significantly with liraglutide only, not with lifestyle counselling.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, IGF-II blood levels rose with liraglutide but not with lifestyle counselling.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum IGF-II level
    Study

    n: not reported in source

    Comparator
    Lifestyle counseling
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    IGF-II serum levels were significantly increased (P = 0.024)
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  6. 06HumanRandomized controlled trialMechanism

    In obese adults with prediabetes or early type 2 diabetes given liraglutide, the IGF-II increase correlated with the decrease in visceral adipose tissue, at borderline significance (rho -0.435).

    In plain wordsIn obese adults on liraglutide, a bigger IGF-II rise was linked to a bigger drop in belly fat, but the link was borderline.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of IGF-II increase with visceral fat decrease
    Study

    n: not reported in source

    Comparator
    Lifestyle counseling
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Measurements

    Correlation rho
    −0.435 NA
    IGF-II increase vs VAT change

    Source sentences

    Summary
    and the increase in IGF-II levels correlated with both a decrease in VAT (ρ = -0.435, P = 0.056) and an increase in the β-index (ρ = 0.55, P = 0.012).
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.
  7. 07HumanRandomized controlled trialMechanism

    In obese adults with prediabetes or early type 2 diabetes given liraglutide, the IGF-II increase correlated with the increase in the beta-index (rho 0.55).

    In plain wordsIn obese adults on liraglutide, a bigger IGF-II rise was linked to a bigger improvement in insulin-producing cell function.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of IGF-II increase with beta-index increase
    Study

    n: not reported in source

    Comparator
    Lifestyle counseling
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Measurements

    Correlation rho
    0.55 NA
    IGF-II increase vs beta-index change

    Source sentences

    Summary
    and the increase in IGF-II levels correlated with both a decrease in VAT (ρ = -0.435, P = 0.056) and an increase in the β-index (ρ = 0.55, P = 0.012).
    1 context sentence
    Summary · context
    Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.